Skip Navigation


Journal of the National Cancer Institute Advance Access originally published online on June 26, 2009
JNCI Journal of the National Cancer Institute 2009 101(14):972-973; doi:10.1093/jnci/djp182
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
101/14/972    most recent
djp182v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Wolpin, B. M.
Right arrow Articles by Stampfer, M. J.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wolpin, B. M.
Right arrow Articles by Stampfer, M. J.
Related Collections
Right arrowRelated Articles in JNCI
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2009. Published by Oxford University Press.

EDITORIALS

Defining Determinants of Pancreatic Cancer Risk: Are We Making Progress?

Brian M. Wolpin, Meir J. Stampfer

Affiliations of authors: Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA (BMW); Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA (BMW); Department of Epidemiology and Department of Nutrition, Harvard School of Public Health, Boston, MA (MJS); Channing Laboratory, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA (MJS)

Correspondence to: Brian M. Wolpin, MD, MPH, Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115 (e-mail: bwolpin@partners.org).

The first 10% of the full text of this article appears below.

Pancreatic cancer is the fourth leading cause of cancer-related mortality in the United States, and 80%–85% of patients have incurable disease at the time of diagnosis. Furthermore, more than 95% of patients diagnosed with pancreatic cancer will ultimately die from the disease, highlighting the urgent need for novel insights into pancreatic tumorigenesis.

Why has progress been so slow in defining predisposing factors for pancreatic cancer? First, its incidence rate is relatively low, when compared with other leading causes of cancer-related death, such as colorectal or breast cancer, so that fewer cases are available for study. Second, . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related Articles in JNCI

IN THIS ISSUE
J Natl Cancer Inst 2009 101: 969. [Extract] [Full Text] [PDF]

Dietary Fat Linked to Pancreatic Cancer
J Natl Cancer Inst 2009 101: 969. [Extract] [Full Text] [PDF]